Search Results - "Bobinski, Thomas P."

Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of MTAP-Deleted Cancers by Smith, Christopher R, Aranda, Ruth, Bobinski, Thomas P, Briere, David M, Burns, Aaron C, Christensen, James G, Clarine, Jeffery, Engstrom, Lars D, Gunn, Robin J, Ivetac, Anthony, Jean-Baptiste, Ronald, Ketcham, John M, Kobayashi, Masakazu, Kuehler, Jon, Kulyk, Svitlana, Lawson, J. David, Moya, Krystal, Olson, Peter, Rahbaek, Lisa, Thomas, Nicole C, Wang, Xiaolun, Waters, Laura M, Marx, Matthew A

“…The PRMT5•MTA complex has recently emerged as a new synthetically lethal drug target for the treatment of MTAP-deleted cancers. Here, we report the discovery…”
Get full text

Citric acid mediated catalytic osmylation/oxidative cleavage of electron deficient olefins: a vinyl sulfone study by Bobinski, Thomas P., Fuchs, Philip L.

“…[Display omitted] The first broad catalytic dihydroxylation of enantiopure cyclic vinyl sulfones followed by oxidative cleavage of the resulting acyloin…”
Get full text

Mechanism-specified 5-exo termini differentiation of a C32-desmethyl C28–C34 aplyronine A analog segment by Bobinski, Thomas P., Fuchs, Philip L.

“…[Display omitted] A new mild, high yielding oxidative cleavage method allows access to a critical lactone aplyronine A analog precursor. Enhanced termini…”
Get full text

Abstract ND04: Discovery of ORIC-944, a novel inhibitor of PRC2 with best-in-class properties for the treatment of prostate cancer by Marx, Matthew A., Burns, Aaron C., Arora, Nidhi, Bobinski, Thomas P., Briere, David M., Calinisan, Andrew, Gunn, Robin J., Ketcham, John M., Lawson, David, Lee, Matthew, Olson, Peter, Smith, Christopher R., Sudhakar, Niranjan, Christensen, James G., Chen, Chelsea X., Yuen, Natalie, Ulicna, Livia, Duong, Frank, Colas, Christophe, Ramnath, Anjana, Xu, Ron, Maneval, Edna Chow, Multani, Pratik S., Patel, Rupal, Kumar, Archana, Daemen, Anneleen, Romero, Anthony, Junttila, Melissa R., Friedman, Lori S.

“…First generation inhibitors of PRC2 (Polycomb Repressive Complex 2) targeting EZH2 (Enhancer of Zeste Homolog 2) achieved clinical proof-of-concept in…”
Get full text